Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)
- 1 March 2005
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 95 (5), 581-585
- https://doi.org/10.1016/j.amjcard.2004.11.003
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventionsThe American Journal of Cardiology, 2003
- Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventionsAmerican Heart Journal, 2003
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary InterventionJAMA, 2003
- Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)The American Journal of Cardiology, 2003
- Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiencyThe American Journal of Cardiology, 2002
- The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventionsJournal of the American College of Cardiology, 2002
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa ReceptorsNew England Journal of Medicine, 1999
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976